Structural Biology of Cell Signalling
Dr Sebastian Guettler’s group is researching the ways in which certain enzymes, known as ADP-ribosyltransferases (ARTs), control cell function.
Professor Sebastian Guettler
Deputy Head of Division:
Structural Biology of Cell Signalling.jpg?sfvrsn=4c485212_1 "Sebastian_Guettler_2 (1)")
Professor Sebastian Guettler is Deputy Head of the Division of Structural Biology. He studies the precise molecular mechanisms of signalling processes central to cancer stem cell function, with a particular interest in Wnt/β-catenin signalling, telomere length homeostasis and their regulation by ADP-ribosylation. He has a long-standing interest in understanding tankyrase, a poly-ADP-ribosyltransferase with roles in both Wnt/β-catenin signalling and telomere maintenance.
Researchers in this group
.
Email: [email protected]
Location: Chelsea
I completed my MChem at the University of York in Chemistry, Medicinal and Biological Chemistry, with a year in industry, where I worked at UCB Pharma, in the Medicinal Chemistry department. My Masters project was on a drug discovery project in peptide therapeutics. After this, I completed a 10-week internship in organic chemistry at AstraZeneca. I then worked as a Junior Medicinal Chemist for a year, at Autifony Therapeutics, working in CNS drug discovery. For my PhD, an MRC iCASE-funded project, I aim to develop small molecules targeting the telomeric Shelterin complex, jointly in Sebastian Guettler's and Swen Hoelder's groups at the ICR, with Merck as our industry partner.
.
Phone: +44 20 3437 6624
Email: [email protected]
I graduated from the University of Southampton, with an integrated Master’s in Biochemistry (MSc). For my bachelor’s project, I investigated the effects of reactive oxygen species and vitamin C on S100A9 aggregation in Alzheimer’s disease. For my Master’s project, I investigated the functional importance of Snap29 for mitosis in Drosophila. For my PhD, I study the molecular mechanisms of telomere maintenance.
.
I graduated from the University of Manchester, with a BSc in Biochemistry with industrial experience (IE). I spent my IE at Mayo Clinic in Jacksonville, Florida, investigating mitochondrial dysfunction in disease. In 2020, I joined the Guettler lab to study how tankyrase regulates Wnt/β-catenin signalling utilising genetic techniques. I completed my PhD in the end of 2024.
.
Email: [email protected]
Location: Chelsea
Oviya studied Biotechnology during her undergraduate degree at SRM University, India. She then completed her PhD in Professor Sara Sandin's lab at Nanyang Technological University, Singapore. Oviya joined the ICR as a postdoc in 2019 and is currently studying the function of tankyrase at telomeres.
.
I completed my BSc degree at the University of West Indies (UWI), in Kingston Jamaica. I then pursued an MSc degree at the University College London (UCL), where I characterised a novel cause of Silver-Russell Syndrome in the lab of Professor Gudrun Moore. Subsequently, I ventured off to Zürich, where I joined the lab of Professor Ulrike Kutay at the Institute of Biochemistry, ETH Zürich, as a PhD student. My PhD research identified mammalian inner nuclear membrane proteins that majorly contribute to the establishment and the maintenance of 3D genome architecture, and the resulting biological consequences when this organisation is perturbed. I joined the Guettler Lab as a Postdoc in October 2025, and my work involves investigating the molecular mechanisms of tankyrase, particularly in Wnt/β-catenin signalling and telomere length homeostasis.
.
Katy completed her MChem degree at Durham University in 2023, where her final-year research project focussed on the application of peptidomimetics to generate novel therapeutics for Alzheimer's disease. At the ICR, she's working on a collaborative project with Professor Sebastian Guettler and Professor Swen Hoelder, developing novel scaffolding inhibitors of tankyrase.
.jpg?sfvrsn=99b8ef9b_1)
.
I completed my B.Tech in Chemical Engineering from Anna University in Chennai, India, in 2013. Following my interest in sustainable bioenergy, I pursued an MRes in Sustainable Bioenergy at the School of Biosciences, University of Nottingham, UK, from 2014 to 2016. During my time there, I had the opportunity to intern at the Flow Cytometry Facility based in Queens Medical Centre in Nottingham, which inspired me to pursue higher research studies in basic science. Motivated by my newfound passion, I embarked on a PhD in the prestigious Max Planck Research Group, based at the Malopolska Centre of Biotechnology in Krakow, Poland. My doctoral research focussed on unravelling the mysteries of an ancient ubiquitin-like protein (Urm1) conjugation mechanism called urmylation. To investigate its function, I employed crystallography, mass spectrometry, and biochemical assays, successfully deciphering the intricate workings of urmylation. In May 2023, I joined the Guettler lab to study the molecular mechanisms of the Wnt/β-catenin signalling pathway.
.
I completed my Bachelor's degree in Molecular Biology and in Public Health at Erasmus University College (Rotterdam, NL), during which I did a summer internship at Karolinska Institute (Stockholm, Sweden) in the field of cancer biology under an Amgen fellowship. I continued with my studies at Imperial College London (UK) in Molecular Basis of Human Disease. Throughout the two projects of my Research Master's degree, I studied (1) the effect of histone acetylation on chromatin remodelling and (2) the structure and function of a lipid-binding phosphatase. In Sebastian's lab, I am studying the molecular mechanisms of Wnt/beta-catenin signalling.
.
Dr Vasundara Srinivasan obtained her PhD in Biochemistry from the University of Georgia, USA in the lab of Prof B.C. Wang. She next joined the lab of the Nobel Laureate Prof Hartmut Michel at the Max Planck Institute of Biophysics, Germany to work on membrane proteins, G-protein coupled receptors (GPCR) and transporters, focussing on mitochondrial ABC transporters in collaboration with Prof Roland Lill. As a project leader at the VIB, Brussels, Belgium, she used nanobodies as chaperones for the crystallisation of GPCRs. She headed the crystallisation facility at the University of Marburg before joining the lab of Prof Christian Betzel at DESY, Hamburg to work on the structure-based drug discovery of proteases involved in the replication cycle of SARS-CoV-2. She joined the lab of Prof Sebastian Guettler at the ICR in January 2025.
Professor Sebastian Guettler's group have written 29 publications
Most recent new publication 4/2025
See all their publicationsResearch, projects and publications in this group
ADP-ribosylation is a post-translational modification carried out by ADP-ribosyltransferases (ARTs), which transfer ADP-ribose from NAD+ onto substrates. ADP-ribosylation controls many aspects of cell function, including DNA repair, cell division, telomere maintenance, chromatin dynamics, apoptosis and various signal transduction processes. Given their roles in DNA repair, telomere homeostasis and cancer-relevant signalling pathways, several ARTs are being explored as potential cancer therapy targets.
In humans, the family of intracellular ARTs encompasses 17 members with similar catalytic domains but greatly diverse non-catalytic accessory domains. Different catalytically active ARTs can either transfer a single unit of ADP-ribose or attach ADP-ribose processively, thereby constructing poly(ADP-ribose) (PAR) chains, which can be of varying length and structure. Enzymes in the latter group are known as poly(ADP-ribose)polymerases (PARPs). Compared to other types of post-translational modification, such as phosphorylation, PARylation remains understudied.
We take a particular interest in the PARP enzyme tankyrase, which fulfils a wide range of biological functions, many of which are relevant to cancer. The human genome encodes two highly similar tankyrase paralogues, TNKS and TNKS2. Both share a C-terminal catalytic PARP domain, a set of five N-terminal ankyrin repeat clusters (ARCs) responsible for substrate recruitment, and a polymerising sterile alpha motif (SAM) domain in between.
Our previous structure-function work has revealed the mechanisms of substrate recognition and polymerisation by tankyrase and shown that tankyrase can act as a scaffolding protein, independently of its catalytic function. We now aim to use both X-ray crystallography and cryo-electron microscopy to understand how tankyrase’s various domains act together. Moreover, we work with chemists to develop novel approaches to modulate tankyrase function.
Tankyrase (TNKS, TNKS2) uses its ankyrin repeat clusters (ARCs) to recruit binding partners, many of which are also PARylated by tankyrase’s PARP domain. ARCs recognise degenerate peptide motifs found in many proteins. Our earlier work (Guettler et al., 2011) has revealed the substrate recognition mechanism and explained how the rare human disease Cherubism is caused. The sterile alpha motif (SAM) domain enables tankyrase polymerisation. We have revealed the mechanism of tankyrase polymerisation and shown that both ARCs and the SAM domain polymer fulfil essential scaffolding roles and are required for efficient substrate modification (Mariotti et al., 2016). (Images modified from Guettler et al., 2011; Mariotti et al., 2016 and Pollock et al., 2017)
Molecular mechanisms of Wnt/beta-catenin signalling, telomere maintenance and their regulation by poly(ADP-ribosyl)ation
In a series of projects, we take a reductionist approach to study how large macromolecular complexes coordinate Wnt/beta-catenin signalling and telomere length homeostasis and how they are controlled by tankyrase-dependent poly(ADP-ribosyl)ation. We combine biochemical assays with cryo-electron microscopy and X-ray crystallography to uncover the detailed mechanisms governing the functions of these complexes and their regulation.
Besides uncovering fundamental mechanisms underlying stem and cancer cell function, we endeavour to understand the molecular basis of disease mutations and open up new opportunities for pharmacological intervention.
Wnt/beta-catenin signalling revolves around controlling the levels of the transcriptional co-activator beta-catenin. A multi-protein beta-catenin destruction complex captures cytoplasmic beta-catenin and limits its abundance by initiating its phosphorylation- and ubiquitination-dependent degradation. Notably, destruction complex function is impaired in the vast majority of colorectal cancer cases. Wnt stimulation remodels the destruction complex into a membrane-localised “Wnt signalosome” incapable of destabilising beta-catenin. Tankyrase controls the receptiveness of cells to incoming Wnt signals by PARylating AXIN, thereby destabilising the destruction complex or promoting Wnt signalosome formation. (Images modified from Mariotti et al., 2017)
A small number of key signalling pathways collaborate to confer stem-cell properties to cells, and the Wnt/beta-catenin pathway is a prototypic example for such a pathway. Wnt/beta-catenin signalling plays important roles in embryonic development and adult organ homeostasis. It is dysregulated in a number of different cancer types, most prominently in colorectal cancers, the vast majority of which bear mutations in components of the pathway.
At the same time, stem and most cancer cells rely on active telomerase to prevent erosion of their telomeres and maintain their unlimited replicative potential. Recent findings show that Wnt/beta-catenin signalling and telomere homeostasis are closely intertwined at multiple levels and form an integrated self-renewal programme, relevant to normal tissue regeneration, ageing and cancer.
The poly(ADP-ribose)polymerase (PARP) tankyrase both promotes Wnt/beta-catenin signalling and is essential for normal telomere extension in humans, thereby providing an important link between both processes.
Our overarching goal is to understand the precise molecular mechanisms that underlie Wnt/beta-catenin signalling, telomere maintenance and their control by poly(ADP-ribosyl)ation. We have a long-standing interest in deciphering the structural basis and molecular mechanisms of tankyrase function.
We employ biochemistry, structural biology and cell biology to study the molecular mechanisms of Wnt/beta-catenin signalling and telomere homeostasis, with a particular focus on how poly(ADP-ribosyl)ation (PARylation) controls both processes. Besides understanding fundamental mechanisms of cell function, we aim to uncover novel potential therapeutic avenues in cancer.
We take a multidisciplinary approach to study Wnt/beta-catenin signalling, telomere maintenance and their regulation by poly(ADP-ribosyl)ation. Structural biology is at the centre of our work. (Images modified from Mariotti et al., 2016)
Vacancies at the ICR
Working at the ICR
Principal Statistician
Job Details The Cancer Research UK funded Clinical Trials and Statistics Unit at The Institute of Cancer Research (ICR-CTSU) seek an experienced and highly motivated Principal Statistician to join their team of over 20 statisticians. We want to hear from you if you: Enjoy the challenge of researching, developing and implementing efficient trial methodology, and designing efficient clinical trials that will make a difference in patients’ lives Seek variety in your work and opportunities to apply your statistical knowledge across multiple therapeutic areas in oncology. Thrive on being part of a multi-disciplinary research team with like-minded statisticians. Are looking to develop your career within a dynamic and supportive academic environment at a leading cancer clinical trials unit. Key Requirements The successful applicant will be an experienced and highly motivated medical statistician interested in researching new statistical methods and applying their statistical knowledge to the design and analysis of patient-centred clinical trials. They will have a post-graduate qualification in statistics. They should demonstrate a solid understanding of clinical trials and experience in applying statistical methods to real-world data. Familiarity with Bayesian statistics and early phase adaptive trials are highly desirable. Effective oral and written communication skills, as well as enthusiasm for collaborating with others from diverse disciplines, are essential. Department/Directorate Information ICR-CTSU manages an exciting portfolio of national and international phase II and III cancer clinical trials and an expanding number of phase I trials. You will contribute in shaping the development of methodological innovations and implementing efficient methods in new and ongoing trials, with a specific focus in early phase and adaptive trials. You will work as part of a multi-disciplinary team on trials methodology research and on the statistical development, oversight and analysis of a number of clinical trials within the ICR-CTSU’s Early Phase and Adaptive Trials portfolio in collaboration with external organisations and the ICR/Royal Marsden Drug Development Unit. In your supporting statement please summarise how your research/managerial experience fits with the role. We encourage all applicants to access the job pack attached for more detailed information regarding this role. This is an office-based role. Requests for hybrid working (splitting time between our Sutton site and home) may be considered following successful completion of key training and only if the role allows. Flexible working options may be considered. For informal discussion about the role, please contact Professor Christina Yap, email: [email protected] For general queries about the recruitment process, please contact ICR-CTSU, email: [email protected].
Statistical Assistant – Industry Placement
Summary of Role ICR’s Cancer Research UK Clinical Trials & Statistics Unit (ICR-CTSU) is offering a placement year training opportunity at its Sutton site in Surrey for an enthusiastic, adaptable, and quick learning individual, currently undertaking an undergraduate degree in mathematics, statistics or a related field with a strong statistical component. This an exciting opportunity for students interested in a career within clinical trials to receive training within a clinical research setting. The successful applicant will work directly with the ICR-CTSU Statisticians, Trial & Data managers and Trial administrators to support the delivery of a diverse portfolio of phase II/III clinical trials, with a special emphasis in breast, urological and head and neck cancer treatments. You will receive full training in Good Clinical Practice and experience of working in accordance with UK clinical trials legislation. This will put you ahead of the competition when you graduate if you apply for a role in clinical trials either in academic research or in industry. You should be an undergraduate student (in mathematics, statistics or a related field with a strong statistical component) in your second year of study seeking a placement year opportunity in clinical trials. This post will be office based. When applying please provide a supporting statement; together with your CV and the names and addresses of two referees. Key Requirements The successful candidate must be studying for an undergraduate degree in mathematics, statistics or a related field with a strong statistical component. You should have a high level of computer literacy, a proven ability to use MS office packages and work accurately with attention to detail as well as good written and oral communication skills. You should have the ability to adhere to written procedures, work to agreed deadlines and work as part of a team. An interest in cancer research and medical statistics, and the ability to work with confidential information is also essential. Previous experience of the use of statistical programming languages would be an advantage but is not essential. For full details of the requirements see the job description. Department/Directorate Information For information regarding the ICR-CTSU Team go to: https://www.icr.ac.uk/our-research/centres-and-collaborations/centres-at-the-icr/clinical-trials-and-statistics-unit We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact us via email at: [email protected]
Employee Story
Dr Federico Tidu is a Postdoctoral Training Fellow in Dr Christian Zierhut’s Cancer Biology – Genome Stability and Innate Immunity Team. He and his team are based in our Chester Beatty Laboratories building in Chelsea, Central London.
"Working in Chelsea is great and there’s a very good community here."
Industrial partnership opportunities with this group
Opportunity: Biomarker for CDK4/6 and/or aromatase inhibitor response in breast cancers
Commissioner: Dr Maggie Cheang
Recent discoveries from this group
